ArticleAntimicrobial agents and chemotherapy2015
Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 79 citations in OpenAlex.
- Heme as activator and target for artemisinin: Towards multiple pharmacological bioactivity.Biochemistry and biophysics reports · 2026Review
- Non-antifungal medications administered during fungal infections drive drug tolerance and resistance inJournal of medical microbiology · 2025Article
- Bioactive Phytophenolics of Vitex negundo Reveal Therapeutic Antifungal Potentials against Candida albicans.Chinese journal of integrative medicine · 2025Article
- Mechanistic insights into antifungal potential of Alexidine dihydrochloride and hexachlorophene in Candida albicans: a drug repurposing approach.Archives of microbiology · 2024Article
- Artemisinin May Disrupt Hyphae Formation by Suppressing Biofilm-Related Genes ofAntibiotics (Basel, Switzerland) · 2024Article
- SynergisticFrontiers in cellular and infection microbiology · 2024Article
- The combination of allicin with domiphen is effective against microbial biofilm formation.Frontiers in microbiology · 2024Article
- Antifungal therapy ofBiofilm · 2023Article
- Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance.RSC medicinal chemistry · 2023Review
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Antifungal Activity of Extracts, Fractions, and Constituents fromPharmaceuticals (Basel, Switzerland) · 2021Article
- Article
- Current and promising pharmacotherapeutic options for candidiasis.Expert opinion on pharmacotherapy · 2021Article
- Enhanced Efficacy of Thiosemicarbazone Derivative-Encapsulated Fibrin Liposomes against Candidiasis in Murine Model.Pharmaceutics · 2021Article
- Mechanistic Understanding ofFrontiers in microbiology · 2021Review
- Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth.Molecular cancer therapeutics · 2021Article
- Strategies for Interfering With Bacterial Early Stage Biofilms.Frontiers in microbiology · 2021Review
- Combination of AgNPs and Domiphen is Antimicrobial Against Biofilms of Common Pathogens.International journal of nanomedicine · 2021Article
- A Screen for Small Molecules to TargetJournal of fungi (Basel, Switzerland) · 2020Article
- Combination Therapy to Treat Fungal Biofilm-Based Infections.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal biofilm-related fungal infections are very common, and the incidence of recurrent oral and vulvovaginal candidiasis is significant. As resistance to azoles (the preferred treatment) is occurring, we aimed at identifying compounds that increase the activity of miconazole against Candida albicans biofilms. We screened 1,600 compounds of a drug-repositioning library in combination with a subinhibitory concentration of miconazole. Synergy between the best identified potentiators and miconazole was characterized by checkerboard analyses and fractional inhibitory concentration indices. Hexachlorophene, pyrvinium pamoate, and artesunate act synergistically with miconazole in affecting C. albicans biofilms. Synergy was most pronounced for artesunate and structural homologues thereof. No synergistic effect could be observed between artesunate and fluconazole, caspofungin, or amphotericin B. Our data reveal enhancement of the antibiofilm activity of miconazole by artesunate, pointing to potential combination therapy consisting of miconazole and artesunate to treat C. albicans biofilm-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.